OncoMatch/Clinical Trials/NCT06414148
MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma
Is NCT06414148 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Epcoritamab and Epcoritamab, lenalidomide and rituximab for relapsed/refractory large b-cell lymphoma.
Treatment: Epcoritamab · Epcoritamab, lenalidomide and rituximab — This is a Phase II open-label, two-arm randomised non-comparative, multi-centre study to evaluate the efficacy of Epcor-only (Epcoritamab alone) or Epcor-R2 (Epcoritamab, lenalidomide and rituximab) as consolidation post anti-CD19 CAR T-cell therapy for patients that have responded by conventional criteria but who are at high risk of progression by virtue of being Minimal Residual Disease (MRD) positive as determined by a Circulating Tumour DNA (ctDNA) assay.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 CAR T-cell therapy received
Received...anti-CD19 CAR T-cell therapy as the most recent large B-cell lymphoma treatment
Excluded: CD20 negative
Patients whose lymphoma is known to be CD20 negative on the most recent biopsy prior to CAR T-cell therapy
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: anti-CD19 CAR-T cell therapy — most recent large B-cell lymphoma treatment
Received...anti-CD19 CAR T-cell therapy as the most recent large B-cell lymphoma treatment
Cannot have received: bispecific antibody targeting CD3 and CD20
Progression or relapse within 3 months after a regimen containing a bispecific antibody targeting CD3 and CD20
Lab requirements
Blood counts
Adequate haematological function documented within 7 days prior to randomisation
Kidney function
Adequate renal function, documented within 7 days prior to randomisation
Liver function
Adequate hepatic function documented within 7 days prior to randomisation
Cardiac function
Adequate cardiac function
Adequate haematological function documented within 7 days prior to randomisation; Adequate cardiac function; Adequate renal function, documented within 7 days prior to randomisation; Adequate hepatic function documented within 7 days prior to randomisation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06414148 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bispecific antibody targeting CD3 and CD20 disqualifies patients from enrollment.
Does this trial require CD19?
Yes, CD19 CAR T-cell therapy received is a required biomarker for enrollment.
Are patients with CD20 alterations eligible?
No. CD20 negative is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify